Palliative Care, End-of-Life Care, and Advance Care Planning in Neuro-oncology

CONTINUUM Lifelong Learning in Neurology

Volumn 23, Issue 6, Neuro-oncology, 2017, Pages 1709-1726

  Walbert, Tobias ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCE CARE PLANNING; BRAIN TUMOR; CANCER FATIGUE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; HEADACHE; HOSPICE CARE; MEDICAL SPECIALIST; NAUSEA; PRIMARY MEDICAL CARE; REVIEW; SEIZURE; CAREGIVER; GLIOMA; HUMAN; PALLIATIVE THERAPY; PSYCHOLOGY; QUALITY OF LIFE; TERMINAL CARE;

ADVANCE CARE PLANNING; CAREGIVERS; GLIOMA; HUMANS; PALLIATIVE CARE; QUALITY OF LIFE; TERMINAL CARE;

EID: 85037108492     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000538     Document Type: Review

References (63)

1. Buckner JC Shaw EG Pugh SL. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016; 374 (14): 1344-1355. doi:10.1056/NEJMoa1500925.
2. Stupp R Mason WP van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10): 987-996. doi:10.1056/NEJMoa043330.
3. Edelstein K Coate L Massey C. Illness intrusiveness and subjective well-being in patients with glioblastoma. J Neurooncol 2016; 126 (1): 127-135. doi:10.1007/s11060-015-1943-6.
4. Song K Amatya B Voutier C Khan F. Advance care planning in patients with primary malignant brain tumors: A systematic review. Front Oncol 2016; 6: 223. doi:10.3389/fonc.2016.00223.
5. World Health Organization. WHO Definition of palliative care. who.int/cancer/palliative/definition/en/. Accessed October 3, 2017.
6. Creutzfeldt CJ Robinson MT Holloway RG. Neurologists as primary palliative care providers: communication and practice approaches. Neurol Clin Pract 2016; 6 (1): 40-48. doi:10.1212/CPJ.0000000000000213.
7. Walbert T. Integration of palliative care into the neuro-oncology practice: patterns in the United States. Neurooncol Pract 2014; 1 (1): 3-7. doi:10.1093/nop/npt004.
8. Armstrong TS Mendoza T Gning I. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol 2006; 80 (1): 27-35. doi:10.1007/s11060-006-9135-z.
9. Sizoo EM Pasman HR Dirven L. The end-of-life phase of high-grade glioma patients: A systematic review. Support Care Cancer 2014; 22 (3): 847-857. doi:10.1007/s00520-013-2088-9.
10. Walbert T Khan M. End-of-life symptoms and care in patients with primary malignant brain tumors: A systematic literature review. J Neurooncol 2014; 117 (2): 217-224. doi:10.1007/s11060-014-1393-6.
11. Page TS Chang SM. Creating a caregiver program in neuro-oncology. Neurooncol Pract 2016: 4 (2): 116-122. doi:10.1093/nop/npw019.
12. Armstrong TS. Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials. Curr Oncol Rep 2013: 15 (1): 27-32. doi:10.1007/s11912-012-0276-2.
13. University of Texas MD Anderson Cancer Center website. MD Anderson Symptom Inventory-Brain Tumor. www3.mdanderson.org/depts/symptomresearch/pdf/MDASI-BrainTumor%20-%20SAMPLE.pdf. Accessed October 3, 2017.
14. Institute of Medicine. Dying in America: improving quality and honoring individual preferences near the end of life. Washington, DC: National Academies Press, 2014.
15. Quill TE Abernethy AP. Generalist plus specialist palliative care-creating a more sustainable model. N Engl J Med 2013; 368 (1): 1173-1175. doi:10.1056/NEJMp1215620.
16. Walbert T Glantz M Schultz L Puduvalli VK. Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: A North-American survey. J Neurooncol 2016; 126 (2): 337-345. doi:10.1007/s11060-015-1973-0.
17. Hui D Elsayem A De la Cruz M. Availability and integration of palliative care at US cancer centers. JAMA 2010; 303 (11): 1054-1061. doi:10.1001/jama.2010.258.
18. Ferrell BR Temel JS Temin S. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017; 35 (1): 96-112. doi:10.1200/JCO.2016.70.1474.
19. Temel JS Greer JA Muzikansky A. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363 (8): 733-742. doi:10.1056/NEJMoa1000678.
20. Neil E McCabe M Carver A, Ethical conflicts at the end of life in patients with malignant brain tumors. Paper presented at: 68th Annual Meeting of the American Academy of Neurology; April 2016. Vancouver, BC.
21. Diamond EL Russell D Kryza-Lacombe M. Rates and risks for late referral to hospice in patients with primary malignant brain tumors. Neuro Oncol 2016; 18 (1): 78-86. doi:10.1093/neuonc/nov156.
22. Gofton TE Graber J Carver A. Identifying the palliative care needs of patients living with cerebral tumors and metastases: A retrospective analysis. J Neurooncol 2012; 108 (3): 527-534. doi:10.1007/s11060-012-0855-y.
23. Fritz L Dirven L Reijneveld JC. Advance care planning in glioblastoma patients. Cancers (Basel) 2016; 8 (11). doi: 10.3390/cancers8110102.
24. Loghin M Levin VA. Headache related to brain tumors. Curr Treat Options Neurol 2006; 8 (1): 21-32. doi:10.1007/s11940-996-0021-y.
25. Pfund Z Szapáry L Jászberényi O. Headache in intracranial tumors. Cephalalgia 1999; 19 (9): 787-790; discussion 765. doi: 10.1046/j.1468-2982.1999.1909787.x.
26. Forsyth PA Posner JB. Headaches in patients with brain tumors: A study of 111 patients. Neurology 1993; 43 (9): 1678-1683. doi:10.1212/WNL.43.9.1678.
27. Gonzalez J Kumar AJ Conrad CA Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007; 67 (2): 323-326. doi:10.1016/j.ijrobp.2006.10.010.
28. Bower JE Bak K Berger A. Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 2014; 32 (17): 1840-1850. doi:10.1200/JCO.2013.53.4495.
29. Lovely MP Miaskowski C Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum 1999; 26 (5): 921-925.
30. Valko PO Siddique A Linsenmeier C. Prevalence and predictors of fatigue in glioblastoma: A prospective study. Neuro Oncol 2015; 17 (2): 274-281. doi:10.1093/neuonc/nou127.
31. Armstrong TS Cron SG Bolanos EV. Risk factors for fatigue severity in primary brain tumor patients. Cancer 2010; 116 (11): 2707-2715. doi:10.1002/cncr.25018.
32. Struik K Klein M Heimans JJ. Fatigue in low-grade glioma. J Neurooncol 2009; 92 (1): 73-78. doi:10.1007/s11060-008-9738-7.
33. Armstrong TS Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro Oncol 2012; 14 (suppl 4): iv65-iv72. doi:10.1093/neuonc/nos210.
34. Rooney AG Carson A Grant R. Depression in cerebral glioma patients: A systematic review of observational studies. J Natl Cancer Inst 2011; 103 (1): 61-76. doi:10.1093/jnci/djq458.
35. Asher A Fu JB Bailey C Hughes JK. Fatigue among patients with brain tumors. CNS Oncol 2016; 5 (2): 91-100. doi:10.2217/cns-2015-0008.
36. Cramp F Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008;(2): CD006145. doi:10.1002/14651858.CD006145.pub2.
37. Kangas M Bovbjerg DH Montgomery GH. Cancer-related fatigue: A systematic and meta-Analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 2008; 134 (5): 700-741. doi:10.1037/a0012825.
38. Boele FW Klein M Reijneveld JC. Symptom management and quality of life in glioma patients. CNS Oncol 2014; 3 (1): 37-47. doi:10.2217/cns.13.65.
39. Gehring K Patwardhan SY Collins R. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 2012; 107 (1): 165-174. doi:10.1007/s11060-011-0723-1.
40. Butler JM Jr Case LD Atkins J. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-Threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007; 69 (5): 1496-1501. doi:10.1016/j.ijrobp.2007.05.076.
41. Meyers CA Weitzner MA Valentine AD Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998; 16 (7): 2522-2527. doi:10.1200/JCO.1998.16.7.2522.
42. Page BR Shaw EG Lu L. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro Oncol 2015; 17 (10): 1393-1401. doi:10.1093/neuonc/nov084.
43. Day J Yust-Katz S Cachia D. Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev 2016; 4: CD011376. doi:10.1002/14651858.CD011376.pub2.
44. Boele FW Douw L de Groot M. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: A multicenter randomized controlled trial. Neuro Oncol 2013; 15 (10): 1420-1428. doi:10.1093/neuonc/not102.
45. Navari RM Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 374 (14): 1356-1367. doi:10.1056/NEJMra1515442.
46. Roila F Molassiotis A Herrstedt J. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27 (suppl 5): v119-v133. doi:10.1093/annonc/mdw270.
47. Hesketh PJ Bohlke K Lyman GH. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 2016; 34 (4): 381-386. doi:10.1200/JCO.2015.64.3635.
48. Flechl B Ackerl M Sax C. The caregivers' perspective on the end-of-life phase of glioblastoma patients. J Neurooncol 2013; 112 (3): 403-411. doi:10.1007/s11060-013-1069-7.
49. Koekkoek JA Dirven L Reijneveld JC. End of life care in high-grade glioma patients in three European countries: A comparative study. J Neurooncol 2014; 120 (2): 303-310. doi:10.1007/s11060-014-1548-5.
50. Minaya Flores P Berbis J Chinot O Auquier P. Assessing the quality of life among caregivers of patients with gliomas. Neurooncol Pract 2014; 1 (4): 191-197. doi:10.1093/nop/npu027.
51. Oberndorfer S Lindeck-Pozza E Lahrmann H. The end-of-life hospital setting in patients with glioblastoma. J Palliat Med 2008; 11 (1): 26-30. doi:10.1089/jpm.2007.0137.
52. Sizoo EM Pasman HR Buttolo J. Decision-making in the end-of-life phase of high-grade glioma patients. Eur J Cancer 2012; 48 (2): 226-232. doi:10.1016/j.ejca.2011.11.010.
53. Sizoo EM Taphoorn MJ Uitdehaag B. The end-of-life phase of high-grade glioma patients: dying with dignity? Oncol 2013; 18 (2): 198-203. doi:10.1634/theoncologist.2012-0247.
54. Houben CH Spruit MA Groenen MT. Efficacy of advance care planning: A systematic review and meta-Analysis. J Am Med Dir Assoc 2014; 15 (7): 477-489. doi:10.1016/j.jamda.2014.01.008.
55. Triebel KL Martin RC Nabors LB Marson DC. Medical decision-making capacity in patients with malignant glioma. Neurology 2009; 73 (24): 2086-2092. doi:10.1212/WNL.0b013e3181c67bce.
56. Walbert T Pace A. End-of-life care in patients with primary malignant brain tumors: early is better. Neuro Oncol 2016; 18 (1): 7-8. doi:10.1093/neuonc/nov241.
57. Andreassen P Neergaard MA Brogaard T. The diverse impact of advance care planning: A long-Term follow-up study on patients' and relatives' experiences. BMJ Support Palliat Care 2015. pii:bmjspcare-2015-000886. doi:10.1136/bmjspcare-2015-000886.
58. Parker SM Clayton JM Hancock K. A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information. J Pain Symptom Manage 2007; 34 (1): 81-93. doi:10.1016/j.jpainsymman.2006.09.035.
59. Back AL Anderson WG Bunch L. Communication about cancer near the end of life. Cancer 2008; 113 (7 suppl): 1897-1910. doi:10.1002/cncr.23653.
60. VitalTalk. Transitions/goals of care-Addressing goals of care: using the REMAP tool. vitaltalk.org/guides/transitionsgoals-of-care/. Accessed October 3, 2017.
61. Koekkoek JAF Dirven L Reijneveld JC. Epilepsy in the end of life phase of brain tumor patients: A systematic review. Neurooncol Pract 2014; 1 (3): 134-140. doi:10.1093/nop/npu018.
62. Koekkoek JA Postma TJ Heimans JJ Reijneveld JC Taphoorn MJ. Antiepileptic drug treatment in the end-of-life phase of glioma patients: A feasibility study. Support Care Cancer 2016; 24 (4): 1633-1638. doi:10.1007/s00520-015-2930-3.
63. Anderson GD Saneto RP. Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev 2012; 64 (10): 911-918. doi:10.1016/j.addr.2012.01.017.